GlassScriptPhysician profile
Philip D Veatch
NPI 1174503718
$10,172.57
in general payments reported to CMS, 2019-2025
42 companies · $1,525 in 2025
The $1,525 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,583 · 2020: $470 · 2021: $1,338 · 2022: $1,377 · 2023: $2,044 · 2024: $1,837 · 2025: $1,525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,320 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,320.21 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,382.56 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $984.85 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $975.55 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $762.33 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $687.49 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $603.87 | 2019-2025 | Otezla, Repatha, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $564.06 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $371.11 | 2019-2024 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $349.16 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $291.30 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $290.59 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $242.96 | 2022-2025 | Gvoke Hypopen |
| Sumitomo Pharma America, INC. | $217.37 | 2023-2025 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $203.25 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $196.25 | 2019-2023 | Seglentis |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Veatch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.